Medimmune Limited

Medical Research Council

Cambridge Antibody Technology Limited

Other

Ronald Henry Jackson

Gregory Paul Winter

Kevin Stuart Johnson

James David Marks

Andrew David Griffiths

John Gerald McCafferty

Anthony Richard Pope

Timothy Peter Bonnert

David John Chiswell

Timothy Piers Clackson

Kaspar Philipp Holliger

Henricus Renerus Jacobus Mattheus Hoogenboom

David Fairman

Maria Aleksandra Bednarek

Jacqueline Metcalfe

Rasmus Jansson Lofmark

Maria Fritsch-Fredin

Balaji Agoram

Lambertus Benthem

Nicole Burmeister

Madeleine Antonsson

Tristan J Vaughan

Alison Jane Wilton

Philip Ronald Tempest

Hendricus Renerus Jacobus Mattheus Hoogenboom

Andrew James Williams

Julia Elizabeth Thompson

Kasper Philipp Holliger

Henricus Renerus Hoogenboom

Steven Paul Ruddock

Raymond Paul Field

Louise Bacon

Jonathan Alexander Green

Hendricus Reneus Jacobus Mattheus Hoogenboom

Jaqueline Metcalfe

This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.

Glucagon/GLP-1 agonists for the treatment of obesity

A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a filamentous bacteriophage particle containing DNA encoding the sbp member, wherein the sbp member has a binding domain that consists of a dAb fragment. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected filamentous bacteriophage particles for expression of the selected sbp members.

Methods for producing members of specific binding pairs

A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.

A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA.

Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF&#x3b2;) bind specifically isoforms TGF&#x3b2;2 and TGF&#x3b2;1 or both, preferentially compared with TGF&#x3b2;3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF&#x3b2;2, neutralizing its activity, but does not bind the latent member.

Human antibodies specific for TGF&#x3b2;2

Growing community of inventors

Cambridge, United Kingdom

Ronald Henry Jackson